CN111246854A - 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途 - Google Patents

编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途 Download PDF

Info

Publication number
CN111246854A
CN111246854A CN201880068068.XA CN201880068068A CN111246854A CN 111246854 A CN111246854 A CN 111246854A CN 201880068068 A CN201880068068 A CN 201880068068A CN 111246854 A CN111246854 A CN 111246854A
Authority
CN
China
Prior art keywords
hsv
another embodiment
composition
modified mrna
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880068068.XA
Other languages
English (en)
Chinese (zh)
Inventor
H·弗里德曼
D·韦斯曼
S·阿瓦斯蒂
G·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to CN202410526392.9A priority Critical patent/CN118370812A/zh
Publication of CN111246854A publication Critical patent/CN111246854A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880068068.XA 2017-08-17 2018-08-17 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途 Pending CN111246854A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410526392.9A CN118370812A (zh) 2017-08-17 2018-08-17 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762546648P 2017-08-17 2017-08-17
US62/546,648 2017-08-17
US201862701019P 2018-07-20 2018-07-20
US62/701,019 2018-07-20
PCT/IB2018/056210 WO2019035066A1 (en) 2017-08-17 2018-08-17 MODIFIED MHRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410526392.9A Division CN118370812A (zh) 2017-08-17 2018-08-17 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途

Publications (1)

Publication Number Publication Date
CN111246854A true CN111246854A (zh) 2020-06-05

Family

ID=65362983

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880068068.XA Pending CN111246854A (zh) 2017-08-17 2018-08-17 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途
CN202410526392.9A Pending CN118370812A (zh) 2017-08-17 2018-08-17 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410526392.9A Pending CN118370812A (zh) 2017-08-17 2018-08-17 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途

Country Status (7)

Country Link
US (3) US11141478B2 (https=)
EP (2) EP4242223A3 (https=)
JP (3) JP7386535B2 (https=)
CN (2) CN111246854A (https=)
AU (2) AU2018316811B2 (https=)
CA (1) CA3073161A1 (https=)
WO (1) WO2019035066A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111568856A (zh) * 2020-06-24 2020-08-25 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法
WO2024131664A1 (zh) * 2022-12-19 2024-06-27 南京奥罗生物科技有限公司 单纯疱疹病毒疫苗及其应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200737A1 (en) * 2017-04-26 2018-11-01 Modernatx, Inc. Herpes simplex virus vaccine
AU2018316811B2 (en) 2017-08-17 2023-07-13 The Trustees Of The University Of Pennsylvania Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
CN113710267B (zh) * 2019-03-12 2025-05-09 生物技术公司 用于前列腺癌的治疗性rna
WO2022002783A1 (en) * 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
US12419948B2 (en) 2020-08-31 2025-09-23 The Broad Institute, Inc. Immunogenic compositions and use thereof
EP4225360A1 (en) 2020-10-08 2023-08-16 Virothera Limited Vaccine compositions
EP4032546A1 (en) * 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Therapeutic viral vaccine
EP4032547A1 (en) * 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
AU2022233957A1 (en) * 2021-03-11 2023-10-12 Redbiotec Ag Vaccine compositions and methods for treating hsv
TW202434263A (zh) * 2023-01-27 2024-09-01 德商拜恩技術股份公司 用於遞送單純疱疹病毒醣蛋白ｃ、醣蛋白ｄ、及醣蛋白ｅ抗原之醫藥組成物及相關方法
WO2024163918A1 (en) 2023-02-02 2024-08-08 University Of Houston System Mrna vaccine for herpes simplex virus
WO2024249967A1 (en) * 2023-06-02 2024-12-05 The Trustees Of The University Of Pennsylvania Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
WO2025030165A1 (en) * 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025030103A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
AU2024318951A1 (en) 2023-08-03 2026-03-12 BioNTech SE Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
WO2025030097A2 (en) * 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025072383A1 (en) 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025109008A1 (en) 2023-11-20 2025-05-30 Redbiotec Ag Novel vaccine compositions and methods for treating hsv
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025175124A1 (en) * 2024-02-15 2025-08-21 Albert Einstein College Of Medicine Recombinant herpes simplex virus glycoprotein b for treatment and prevention of herpes simplex virus infections
WO2025212831A1 (en) * 2024-04-03 2025-10-09 The Trustees Of The University Of Pennsylvania Methods of inducing an anti-hsv b-cell immune response

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102087A1 (en) * 2006-07-20 2008-05-01 Vical, Incorporated Compositions and methods for vaccinating against hsv-2
US20160074506A1 (en) * 2010-07-06 2016-03-17 Novartis Ag Delivery of self-replicating rna using biodegradable polymer particles
CN106102769A (zh) * 2013-12-11 2016-11-09 促进军事医学的亨利·M·杰克逊基金会公司 人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途
CN106470736A (zh) * 2014-05-13 2017-03-01 宾夕法尼亚州大学信托人 包括表达双抗体构建体的aav的组合物及其用途
WO2017070616A2 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
WO2017070623A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine
CN106999572A (zh) * 2014-10-01 2017-08-01 阿德梅杜斯疫苗有限公司 用于诱导对单纯疱疹病毒2型(hsv‑2)的免疫应答的治疗组合物和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
US9284355B2 (en) * 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US20130028925A1 (en) 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
EP3756684A1 (en) * 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN107028886A (zh) 2009-11-04 2017-08-11 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
HRP20181102T1 (hr) * 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
AU2016253972B2 (en) 2015-04-27 2020-01-02 Acuitas Therapeutics Inc. Nucleoside-modified RNA for inducing an adaptive immune response
US10758694B2 (en) 2015-07-09 2020-09-01 Hoyt Medical LLC Systems and methods for treating an airway using a tapered adapter device
CA3040337A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines
WO2018200737A1 (en) 2017-04-26 2018-11-01 Modernatx, Inc. Herpes simplex virus vaccine
AU2018316811B2 (en) 2017-08-17 2023-07-13 The Trustees Of The University Of Pennsylvania Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102087A1 (en) * 2006-07-20 2008-05-01 Vical, Incorporated Compositions and methods for vaccinating against hsv-2
US20120328658A1 (en) * 2006-07-20 2012-12-27 The University Of Washington Compositions and methods for vaccinating against hsv-2
US20160074506A1 (en) * 2010-07-06 2016-03-17 Novartis Ag Delivery of self-replicating rna using biodegradable polymer particles
CN106102769A (zh) * 2013-12-11 2016-11-09 促进军事医学的亨利·M·杰克逊基金会公司 人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途
CN106470736A (zh) * 2014-05-13 2017-03-01 宾夕法尼亚州大学信托人 包括表达双抗体构建体的aav的组合物及其用途
CN106999572A (zh) * 2014-10-01 2017-08-01 阿德梅杜斯疫苗有限公司 用于诱导对单纯疱疹病毒2型(hsv‑2)的免疫应答的治疗组合物和方法
WO2017070616A2 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
WO2017070623A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JASON W. KIELTYKA等: "Probing RNA Hairpins with Cobalt(III)hexammine and Electrospray Ionization Mass Spectrometry" *
NICOLAS ÇUBURU等: "Topical Herpes Simplex Virus 2 (HSV-2) Vaccination with Human Papillomavirus Vectors Expressing gB/gD Ectodomains Induces Genital-Tissue-Resident Memory CD8+ T Cells and Reduces Genital Disease and Viral Shedding after HSV-2 Challenge" *
NORBERT PARDI等: "Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge" *
张华捷等: "Ⅱ型单纯疱疹病毒疫苗的研究进展" *
潘晓瑜等: "靶向UL5小干扰RNA对Ⅱ型单纯疱疹病毒的抑制" *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111568856A (zh) * 2020-06-24 2020-08-25 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法
WO2024131664A1 (zh) * 2022-12-19 2024-06-27 南京奥罗生物科技有限公司 单纯疱疹病毒疫苗及其应用

Also Published As

Publication number Publication date
EP3668520A1 (en) 2020-06-24
US20240024463A1 (en) 2024-01-25
AU2023248194A1 (en) 2023-11-02
JP7674760B2 (ja) 2025-05-12
CN118370812A (zh) 2024-07-23
EP3668520A4 (en) 2021-05-12
JP7386535B2 (ja) 2023-11-27
US11793872B2 (en) 2023-10-24
AU2018316811A1 (en) 2020-03-12
CA3073161A1 (en) 2019-02-21
AU2018316811B2 (en) 2023-07-13
US11141478B2 (en) 2021-10-12
US20210386853A1 (en) 2021-12-16
JP2020531465A (ja) 2020-11-05
EP4242223A3 (en) 2024-03-13
JP2023153423A (ja) 2023-10-17
WO2019035066A1 (en) 2019-02-21
EP4242223A2 (en) 2023-09-13
US20200276300A1 (en) 2020-09-03
JP2025108645A (ja) 2025-07-23

Similar Documents

Publication Publication Date Title
JP7674760B2 (ja) 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用
JP7330590B2 (ja) 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
US11510977B2 (en) Nucleic acid vaccines for coronavirus
US20180296662A1 (en) Sexually transmitted disease vaccines
US20230248818A1 (en) Nucleoside-modified RNA for Inducing an Immune Response Against SARS-CoV-2
CN117043343A (zh) 用于突变型冠状病毒的核酸疫苗
US20240016922A1 (en) Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
AU2024316992A1 (en) Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
WO2024249967A1 (en) Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
HK40100925A (en) Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
CN121866069A (zh) 编码单纯疱疹病毒糖蛋白e和/或糖蛋白i抗原的rna组合物及其用途
WO2025212831A1 (en) Methods of inducing an anti-hsv b-cell immune response
WO2024245317A9 (en) Mutated fragment of vzv glycoprotein e
WO2024163918A1 (en) Mrna vaccine for herpes simplex virus
CN118922194A (zh) 用于递送单纯疱疹病毒抗原的药物组合物及相关方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination